Kornimate/medical-research-clean huggingface dataset:
telephone acceptance and commitment therapy intervention for caregivers of adults with adrd

Conditions: Anxiety; Caregiver Burden

Summary: the purpose of the study is to test if acceptance and commitment therapy (act), a behavioral intervention designed to increase psychological flexibility in the face of challenges, reduces anxiety associated psychological distress in dementia caregivers compared to the control group who will receive self-help and educational materials. this version of act is delivered over the phone in six primary sessions and one booster session.


Eligibility criteria:
inclusion criteria: * listed in adrd patient's chart as primary caregiver or self-identifies as adrd patient's primary caregiver * intends to continue caregiving for ≥12 months * clinically-significant anxiety (score ≥10 on gad-7) * 21 years or older * able to communicate in english * able to provide informed consent exclusion criteria: * caregiver is a non-family member * care recipient is in an assisted living or nursing home (at baseline) * has adrd or other serious mental illness diagnosis such as schizophrenia as determined by icd-10 code or self-report * caregiver is enrolled in an existing adrd collaborative program at eskenazi health, iu health or the va. * caregiver is enrolled in another iu study that is testing a adrd caregiver intervention

Keywords: dementia alzheimer's disease caregiving caregiver anxiety telehealth
prospective database for acute myeloblastic leukemia

Conditions: Leukemia, Myeloblastic, Acute

Summary: prospective database for acute myeloblastic leukemia


Eligibility criteria:
inclusion criteria: * patients with aml

Keywords: aml
contrasting ketogenic and mediterranean diets in individuals with type 2 diabetes and prediabetes: the keto-med trial

Conditions: Diabetes Mellitus, Type 2; PreDiabetes

Summary: the objective of this study is to compare two metabolically distinct diets, wfkd vs med-plus, in order to examine the potential benefits, and unintended consequences, of going beyond a focus on maximally avoiding added sugars and refined grains, to also avoiding legumes, fruits, and whole grains.

the proposed randomized clinical trial will investigate differential population-specific effects of two low-carbohydrate (low-carb) diet patterns, addressing a gap in the evidence base in this area that will lead to 1) improved treatment strategies for common adverse clinical conditions, 2) improved health for these individuals, and 3) long-term decreases in health care costs. this impactful research will advance the field of personalized and precision medicine.

Eligibility criteria:
inclusion criteria: * age ≥18 * diagnosed with type 2 diabetes mellitus, or prediabetes (defined as hba1c \ 100 mg/dl) identify exclusion criteria. * weight \< 110 lb * bmi \> 40 * ldl-c \>190 mg/dl * blood pressure: sbp \> 160 mmhg or dbp: \> 90 mmhg exclusion criteria: * weight \< 110 lb * bmi ≥ 40 * ldl-c \>190 mg/dl * systolic blood pressure (sbp) \> 160 mmhg or diastolic blood pressure (dbp) \> 90 mmhg * diagnosed with type 1 diabetes or history of ketoacidosis * uncontrolled and untreated diabetes (by discretion of study physician) * active cardiovascular disease (in past year with myocardial infarction, coronary stent or bypass surgery) * kidney disease (egfr less than 50 ml/min per 1.73 m2) * liver disease (liver transaminase higher than 3 times the normal range for the laboratory) * symptomatic gallstones * history of bariatric surgery * anemia * taking any of the following medications in past 3 months: sglt-2 inhibitors, glp-1 receptor agonist, insulin, amylin analog, alpha-glucosidase inhibitor, dopamine agonist, bile acid sequestrant. * taking any medications for weight loss * history of active cancer in the past 3 years except for squamous or basal cell carcinomas of the skin that have been medically managed by local excision * unstable dietary history as defined by major changes in diet during the previous month, where the subject has eliminated or significantly increased a major food group in the diet. * recent history of chronic excessive alcohol consumption defined as more than five 1.5-ounce servings of 80 proof distilled spirits, five 12-ounce servings of beer or five 5-ounce servings of wine per day; or \> 14 drinks/week. * women: pregnant currently or planning to become pregnant during the course of the study, and/or breastfeeding * regular/frequent use of smoking or chewing tobacco, e-cigarettes, cigars or other nicotine-containing products * regular use of prescription opiate pain medication

Keywords: ketogenic diet mediterranean diet diabetes prediabetes
effects of paclitaxel on intimal hyperplasia

Conditions: Peripheral Vascular Disease

Summary: this is a single, one time, limited dose infusion of paclitaxel, that will potentially prevent recurrent stenosis secondary to intimal hyperplasia when compared to the control group at 10 months.

the investigators study consists of enrolling subjects that are already scheduled to have the blood vessels in their legs re-opened. the entire study is considered standard of care, except the administration of paclitaxel. subjects will be consented prior to any study related procedures and prior to procedure. subjects that meet inclusion/exclusion and the infusion of paclitaxel has been given, will then be enrolled in the study. after the plaque area has been treated with either angioplasty (inflation of a balloon compacting it against the artery wall), stent (a wire mesh tube that presses the plaque against the artery wall and opens the artery), and/or atherectomy(removal of plaque from the artery), dr kelly, dr. schultz, dr, laurich, or dr. santos will then use an infusion balloon (a balloon with an outer layer that has holes that allows a medication to be given) to administer the paclitaxel. every time the infusion balloon is blown up, a single dose of medication (paclitaxel) will be applied to the target lesion. this will be repeated until all of the target lesions have been treated or a maximum dose of 10 mg of paclitaxel has been given. all persons enrolled in this study will be treated with paclitaxel. subjects are expected to attend all follow up visits. these visits would occur even if the subject were not on the trial. ankle-brachial index (abi) (done by measuring blood pressure at the ankle and in the arm while a person is at rest. this test indicates if leg blockages are present) and duplexes (an ultrasound that measures blood flow rates through the vessels. this test will indicate if leg blockages are present) will be done at the follow up visits. both of these tests and all follow up visits are considered standard of care and will be charged to the subject or subject's insurance.

Eligibility criteria:
inclusion criteria: * ability to provide informed consent * age 18-90 years old * rutherford 1-6 * occlusion or stenosis in the infrainguinal vessels exclusion criteria: * inability to pass the guide wire across the lesion * pregnant or lactating women * specific limb has not been previously treated with endovascular intervention

Keywords: restenosis peripheral vascular disease lower extremity ischemia claudication
amotosalen and platelet transfusion in adult heart surgery

Conditions: Heart Surgery

Summary: blood safety is ensured by the rigorous selection of donors and biological tests. however, infectious agents can escape this detection and be transmitted to recipients during transfusion. amotosalen is a derivative of psoralens that intercalates with nucleic acids and inactivates them after uv exposure; it therefore makes it possible to inhibit any replication of an infectious agent present. preliminary studies have shown its safety and efficacy in preventing the transmission of infectious agents during the administration of labile blood products (fresh frozen plasma and platelet concentrates) as well as the absence of loss of efficacy (absence of loss of pro-aggregating and procoagulant properties) of the transfused products. in addition, there is a significant reduction in side effects for platelet concentrates, especially compared to irradiated concentrates. treatment of platelet concentrates with amotosalen may be responsible for a reduction in the platelet concentration in each concentrate with an overall decrease in efficiency and transfusion yield compared to untreated concentrates.


Eligibility criteria:
inclusion criteria: * major subjects ≥18 years old * cardiac surgery or ascending aorta * platelet transfusion for any reason * subject not having expressed their opposition, after information, to the reuse of their data for the purposes of this research exclusion criteria * subject having expressed opposition to participating in the study * presence or - installation of transient circulatory assistance (outside of the cec) or definitive * heart or cardiopulmonary transplantation * subject under guardianship or guardianship * subject under safeguard of justice

Keywords: amotosalen platelet transfusion bleeding heart surgery
well-being in cancer patients with neuropathy during covid-19 who participated in prior clinical trials

Conditions: COVID-19 Infection; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Neuropathy

Summary: this study investigates the experiences of cancer patients with neuropathy during the covid-19 pandemic to learn how the covid-19 pandemic affects their quality of life and clinical outcomes. this study will also explore whether there are differences between patients who received neurofeedback (nfb, a type of therapy that is thought to help normalize brain activity) and those who did not. learning about quality of life in cancer patients with neuropathy during the covid-19 pandemic may help guide development of programs and policies to improve chronic pain patient care and outcomes during a major global healthcare crisis.

primary objectives: i. assess experiences during the coronavirus disease 2019 (covid-19) pandemic of the health-related quality of life (hrqol) (e.g. physical, emotional, social well-being), and other covid-19-specific domains (e.g. anxiety, social interactions, finances), and the associations between covid-19 experiences and covid-19-specific distress, hrqol and clinical outcomes of patients who participated in one of three clinical trials. ii. examine differences in outcomes between neuropathic pain patients who participated in one of two trials of nfb and received nfb, and neuropathic pain patients who participated in a non-treatment-related neuropathy study (i.e., who did not receive nfb). iii. evaluate the extent to which coping and resilience factors moderate the effects of covid-19 experiences on covid-19-specific distress, hrqol and clinical outcomes. outline: patients complete an online questionnaire over 15 minutes about their experiences regarding the covid-19 pandemic including testing, risks of exposure, whether people they know have acquired covid-19, as well as questions on how the pandemic has impacted their quality of life.

Eligibility criteria:
inclusion criteria: * must have participated in one of the following protocols: 2015-0399, 2012-0642, or 2010-0675 * has an active email address or can be contacted by mychart or personal email exclusion criteria: * no evidence of consent from prior clinical trials
improving disease severity

Conditions: Psoriasis; Alopecia Areata; Polymorphous Light Eruption

Summary: phototherapy, including ultraviolet b (uvb) and ultraviolet a (uva) light, has been used to treat a number of dermatologic conditions. psoriasis is one of the most common conditions treated with phototherapy, in which phototherapy is often indicated for extensive disease with contraindications for other systemic treatments. the mechanism of action of phototherapy for the treatment of psoriasis is not completely understood; however, it is known that uvb light induces apoptosis of pathogenic t cells and keratinocytes, which may reduce the overactive immune response and epidermal hyperproliferation. phototherapy has shown some efficacy for other diseases, such as alopecia areata (aa) and polymorphous light eruption (pmle). however, phototherapy is not always an accessible treatment option for patients due to cost or lack of time.

recent advancements in nanotechnology have led to the development of medical devices (lasers and led devices) with unique phototherapy properties that emit radiation in the infrared wavelengths, allowing patients to benefit from the effects of phototherapy treatment in a more convenient way. preclinical studies demonstrated the positive effects of infrared radiation exposure on the skin including, increased collagen synthesis and expression of transforming growth factor-beta1 (tgf-beta1). other studies suggested possible antimicrobial effects from infrared radiation, with decreased colonization of staphylococcus aureus, escherichia coli, and klebsiella pneumoniae on the skin after exposure. compared to other fabric technology, such as far-infrared (fir) fabric technology that reflects body heat, fabric made from lumiton yarn converts external light in the uv and visible spectrum and emits light in the red and near-infrared spectrum for the body. lumiton yarn absorbs energy from 350 nm to 600 nm (the light spectrum from uv to visible red light) and emit energy from 600 to 1000 nm (red, near-infrared spectrum). the lumiton yarn contains red/nir light-emitting dyes. the effectiveness of the technology is proportional to the intensity of the light, with its peak effectiveness under sunlight.

Eligibility criteria:
inclusion criteria: * adult participants ≥18 years of age * participants who live in the us, * participants who are diagnosed with mild-to-severe aa, pmle, or psoriasis * participants have sufficient command of the english language exclusion criteria: * participants less than the age of 18 * participants who do not live in the us * participants who are not diagnosed with mild to severe aa, pmle, or psoriasis * participants without a sufficient command of the english language * participants with concurrent medical conditions that are at risk of confounding the study outcomes * participants currently using concomitant phototherapy
efficacy and safety of oral ut-15c tablets to treat pulmonary arterial hypertension

Conditions: Pulmonary Hypertension

Summary: this study is an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with pah who are currently receiving approved therapy for their pah (i.e., endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor). study visits will occur at 4 week intervals for 16 weeks with the key measure of efficacy being the 6-minute walk test. study procedures include routine blood tests, medical history, physical exams, disease evaluation, and exercise tests. patients who complete all assessments for 16-weeks will also be eligible to enter an open-label, extension phase study (freedom - ext).


Eligibility criteria:
inclusion criteria: * a subject is eligible for inclusion in this study if all of the following criteria apply: * between 18 and 75 years of age, inclusive. * body weight at least 40 kg (approximately 90 lbs.) * pah that is either idiopathic/heritable; associated with appetite suppressant or toxin use; associated with collagen vascular disease; associated with repaired congenital shunts; associated with hiv. * currently receiving an approved endothelin receptor antagonist and/or an approved phosphodiesterase-5 inhibitor for at least 90 days and on a stable dose for at least the last 30 days. * baseline six-minute walk distance (6mwd) between 150-425 meters * previous testing (e.g., right heart catheterization, echocardiography) consistent with the diagnosis of pah. * reliable and cooperative with protocol requirements.
effect of hydrotherapy versus aerobic exercise on pulmonary function on hemiplegic cerebral palsied children

Conditions: To Compare the Effectiveness of Hydrotherapy Versus Aerobic Exercise on Pulmonary Function in Hemiplegic Children With Cerebral Palsy

Summary: cerebral palsy (cp) is the most common motor disability in childhood. respiratory muscle weakness and a low upper to lower chest diameter ratio are common respiratory dysfunction manifestations in those children which negatively affect their quality of life..

objective: to compare the effectiveness of hydrotherapy versus aerobic exercise on pulmonary function in hemiplegic children with cerebral palsy. methods: sixty hemiplegic children (both genders) took part in this research, they were between the ages of 8 to 16, moreover, they were split equally between three groups (a, b and c). the three groups participated in the same conventional physical therapy, group (a) received conventional physical therapy only, group (b) received hydrotherapy, while group (c) received aerobic exercise. pulmonary function tests are measured by six-minute walk test (6-mwt) and spirometer to measure forced vital capacity (fvc), forced expiratory volume in the first second (fev1) as well as fev1/fvc ratio for all children before the beginning and after the end of this study, the treatment program was applied three sessions per week for 12 consecutive weeks.

Eligibility criteria:
inclusion criteria: * ages ranged from 8 to 16 years. * belonged to levels i to ii of the gross motor function classification system (gmfcs). * spasticity ranged from grade 1 to grade 1+ according to modified ashwarth scale. - able to walk, no impairment of sensation or other neurological or psychological problems. * clinically and medically stable and able to understand and follow the instructions exclusion criteria: i) visual and/or auditory defects. ii) significant shortening and/or deformity of lower extremities. iii) other neurological problems that affect balance or mentality (e.g. epilepsy) iv) advanced radiographic alterations comprise (bone destruction, bony ankylosis, knee joint sublaxation as well as epiphysial fracture). v) lower extremity skeletal abnormalities (whether congenital or acquired). vi) cardiopulmonary dysfunction.

Keywords: aerobic exercise; cerebral palsy; children; hemiplegia; pulmonary function
calorie restricted diet and exercise

Conditions: Metabolic Syndrome

Summary: calorie-restricted(cr) diet and exercise were effective to reduce metabolic syndrome(mets), however, its effect on knee functions for mets patients with degenerate meniscus lesions(dmls) was still poorly investigated.

the cr diet and exercise group received a balanced diet with an energy consists carbohydrates 45-65%; fat 20-35%; and protein 10- 35% and a deficit of 600 kcal/day from their daily energy requirement. total daily energy intake of 1200-2000 kcal/day were based on baseline weight, and for safety, no woman was provided with less than 1100 kcals/d and no man less than 1300 kcals/d. the energy of the intake calorie restricted diet per day was calculated based on the detailed composition of meals, such as rice, vegetables, eggs, pork, and beef, using the chinese food composition tables. our diets were cooked with traditional chinese cooking methods such as boiling, stir-frying, and stewing. during the intervention, other lipid-lowering drugs were not allowed to intake supplement as it alters the outcome. participants receive education or counseling by a dietitian for modulations of their caloric intake weekly. the exercise intervention included aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for ≥2 d/week for 6 months. the aerobic exercises included walking on a treadmill, stationary cycling for at least 30 minutes for≥2 d/week. resistance exercises included nine upper-extremity and lower-extremity exercise with weighting lift machines for ≥2 d/week, while, flexibility exercise including the major muscle-tendon groups (a total of 60 s per exercise) for ≥2 d/week. participants performed 1 or 2 sets with 8-12 repetitions of each exercise. the exercise sessions were monitored by telephone video. patients who complete at least 80% of diet restriction and exercise were included in analysis. calorie restricted diet and exercise group contain both the above intervention.

Eligibility criteria:
inclusion criteria: * • must be age between 35 and 70 years old; * clinical diagnosis of metabolic syndrome; exclusion criteria: * • must be able to have no acute knee injury such as car crash or acute sports injury; * must be able to have no knee surgeries history; * must be able to have no rheumatoid arthritis or serious knee osteoarthritis with deformity; * must be able to have no contraindications to mri; * must be able to have no severe cardiopulmonary disease; * must be able to have no musculoskeletal or neuromuscular impairments ; * must be able to have good visual, hearing, or cognitive;
assessment of the efficacy of intratympanic platelet rich plasma for treatment of sensorineural hearing loss.

Conditions: Hearing Loss, Sudden; Hearing Loss, Sensorineural; Hearing Loss

Summary: assessment of the efficacy of intratympanic platelet rich plasma injection for treatment of idiopathic suden sensorineural hearing loss

sensorineural hearing loss is the collective term for hearing damage to the cochlea and auditory nerve and is by far the most common type of hearing loss in adults, accounting for over 90% of all cases. sensorineural hearing loss is a heterogeneous disorder, which can arise due to damage to pathway for sound impulses from the hair cells of inner ear to auditory nerve and less commonly brain. sensorineural hearing loss is a challenge to physicians, as it progresses with age and causes significant reductions in quality of life and there are no treatments to reverse its effects, other than sound amplification with the use of hearing aids or direct auditory nerve stimulation via cochlear implantation. platelet-rich plasma (prp) therapy is a cutting-edge procedure that is revolutionizing the hearing loss and deafness. intratympanic instillation of platelet-rich plasma (prp) does wonder to the hair cells of inner ear, thus improving the hearing.

Eligibility criteria:
inclusion criteria: * patients have sudden idiopathic sensorineural hearing loss exclusion criteria: 1. patients has previous ear surgery. 2. patients has absent cochlea in ct or mri 3. patients has cancer,chronic liver disease, hemodynamic instability,hypofibrinogenemia, platelet dysfunction syndromes, systemic disorder, sepsis, low platelet count.
tidhi mental health in ibd patients study

Conditions: Crohn Disease (CD); Ulcerative Colitis (UC); Inflammatory Bowel Disease (IBD)

Summary: the purpose of this study is to test the impact of healing circuits™; a structured mental health support model on ibd patients. the eligible study participants will be randomly divided into two groups: 1. the group receiving structured mental health support with a social worker and 2. the group receiving structured mental health support via a self-directed online curriculum. both groups will be receiving the same type of therapy, healing circuits™, but the group receiving the therapy via the online self-directed curriculum will be receiving the therapy mostly by web-based video instruction. the two groups will be evaluated over a period of 12 months.


Eligibility criteria:
inclusion criteria: subjects must meet each of the following criteria for enrolment into the study: 1. written informed consent must be obtained and documented. 2. males and females between the ages of 18 and 75 years of age with documented diagnosis of ibd. 3. gad7 or phq9 score of 10 - 15. 4. ability of subject to participate fully in all aspects of this clinical trial. 5. ibd patients who plan to have ongoing medical care at tidhi. exclusion criteria: subjects who exhibit any of the following conditions are to be excluded from the study: 1. plan for change in systemically delivered ibd-related medical therapy in the 3 months after screening. 2. serious underlying psychiatric disorder such as schizophrenia or bipolar disorder. 3. history of illegal drug abuse (excluding marijuana) or alcohol abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures

Keywords: healing circuits